S&P 500   5,059.05 (+1.55%)
DOW   38,888.97 (+0.72%)
QQQ   434.77 (+2.15%)
AAPL   183.27 (+0.52%)
MSFT   410.19 (+1.99%)
META   481.69 (+2.92%)
GOOGL   144.07 (+1.07%)
AMZN   172.12 (+2.09%)
TSLA   194.02 (-0.39%)
NVDA   770.29 (+14.16%)
NIO   5.84 (-2.18%)
AMD   176.37 (+7.35%)
BABA   75.14 (-0.58%)
T   16.67 (-1.94%)
F   12.22 (+0.66%)
MU   84.65 (+3.88%)
CGC   3.43 (-0.29%)
GE   151.26 (+1.47%)
DIS   108.25 (+0.54%)
AMC   4.64 (+1.53%)
PFE   27.30 (-1.34%)
PYPL   57.96 (+0.84%)
XOM   104.40 (-0.43%)
S&P 500   5,059.05 (+1.55%)
DOW   38,888.97 (+0.72%)
QQQ   434.77 (+2.15%)
AAPL   183.27 (+0.52%)
MSFT   410.19 (+1.99%)
META   481.69 (+2.92%)
GOOGL   144.07 (+1.07%)
AMZN   172.12 (+2.09%)
TSLA   194.02 (-0.39%)
NVDA   770.29 (+14.16%)
NIO   5.84 (-2.18%)
AMD   176.37 (+7.35%)
BABA   75.14 (-0.58%)
T   16.67 (-1.94%)
F   12.22 (+0.66%)
MU   84.65 (+3.88%)
CGC   3.43 (-0.29%)
GE   151.26 (+1.47%)
DIS   108.25 (+0.54%)
AMC   4.64 (+1.53%)
PFE   27.30 (-1.34%)
PYPL   57.96 (+0.84%)
XOM   104.40 (-0.43%)
S&P 500   5,059.05 (+1.55%)
DOW   38,888.97 (+0.72%)
QQQ   434.77 (+2.15%)
AAPL   183.27 (+0.52%)
MSFT   410.19 (+1.99%)
META   481.69 (+2.92%)
GOOGL   144.07 (+1.07%)
AMZN   172.12 (+2.09%)
TSLA   194.02 (-0.39%)
NVDA   770.29 (+14.16%)
NIO   5.84 (-2.18%)
AMD   176.37 (+7.35%)
BABA   75.14 (-0.58%)
T   16.67 (-1.94%)
F   12.22 (+0.66%)
MU   84.65 (+3.88%)
CGC   3.43 (-0.29%)
GE   151.26 (+1.47%)
DIS   108.25 (+0.54%)
AMC   4.64 (+1.53%)
PFE   27.30 (-1.34%)
PYPL   57.96 (+0.84%)
XOM   104.40 (-0.43%)
S&P 500   5,059.05 (+1.55%)
DOW   38,888.97 (+0.72%)
QQQ   434.77 (+2.15%)
AAPL   183.27 (+0.52%)
MSFT   410.19 (+1.99%)
META   481.69 (+2.92%)
GOOGL   144.07 (+1.07%)
AMZN   172.12 (+2.09%)
TSLA   194.02 (-0.39%)
NVDA   770.29 (+14.16%)
NIO   5.84 (-2.18%)
AMD   176.37 (+7.35%)
BABA   75.14 (-0.58%)
T   16.67 (-1.94%)
F   12.22 (+0.66%)
MU   84.65 (+3.88%)
CGC   3.43 (-0.29%)
GE   151.26 (+1.47%)
DIS   108.25 (+0.54%)
AMC   4.64 (+1.53%)
PFE   27.30 (-1.34%)
PYPL   57.96 (+0.84%)
XOM   104.40 (-0.43%)

Tarsus Pharmaceuticals (TARS) Earnings Date, Estimates & Call Transcripts

$31.23
+1.10 (+3.65%)
(As of 10:03 AM ET)
Skip Charts & View Estimated and Actual Earnings Data

TARS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TARS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Tarsus Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($1.35)($1.35)($1.35)
Q2 20241($1.50)($1.50)($1.50)
Q3 20241($1.48)($1.48)($1.48)
Q4 20241($1.36)($1.36)($1.36)
FY 20244($5.69)($5.69)($5.69)

TARS Earnings Date and Information

Tarsus Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Tuesday, February 27th, 2024. Tarsus Pharmaceuticals will be holding an earnings conference call on Tuesday, February 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call..

Tarsus Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/27/2024
Confirmed)
-------  
11/9/2023Q3 2023($1.40)($1.28)+$0.12($1.28)$0.72 million$1.87 million
8/10/2023Q2 2023($1.08)($1.17)($0.09)($1.17)--
5/9/2023Q1 2023($0.95)($0.88)+$0.07($0.88)$3.33 million$2.50 million
3/13/2023Q4 2022($0.97)($0.49)+$0.48($0.49)$11.67 million$10.00 million
11/9/2022Q3 2022($0.98)($0.84)+$0.14($0.84)--
8/11/2022Q2 2022($0.65)($0.24)+$0.41($0.24)$16.67 million$15.28 million
5/10/2022Q1 2022($0.87)($0.98)($0.11)($0.98)$5.50 million$0.54 million
3/14/2022Q4 2021($0.77)($0.72)+$0.05($0.72)$7.11 million$0.34 million
11/9/2021Q3 2021($0.42)($0.76)($0.34)($0.76)$1.00 million$1.24 million
8/4/2021Q2 2021($0.52)$0.29+$0.81$0.29$10.00 million$22.02 million
5/11/2021Q1 2021($0.64)$0.47+$1.11$0.47-$33.43 million












Tarsus Pharmaceuticals Earnings - Frequently Asked Questions

When is Tarsus Pharmaceuticals's earnings date?

Tarsus Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Tuesday, February 27th, 2024. Learn more on TARS's earnings history.

How much revenue does Tarsus Pharmaceuticals generate each year?

Tarsus Pharmaceuticals (NASDAQ:TARS) has a recorded annual revenue of $25.82 million.

How much profit does Tarsus Pharmaceuticals generate each year?

Tarsus Pharmaceuticals (NASDAQ:TARS) has a recorded net income of -$62.09 million. TARS has generated -$3.82 earnings per share over the last four quarters.

What is Tarsus Pharmaceuticals's EPS forecast for next year?

Tarsus Pharmaceuticals's earnings are expected to decrease from ($4.88) per share to ($4.93) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:TARS) was last updated on 2/22/2024 by MarketBeat.com Staff